Covid19 Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ZnAg Liquid Solution to Treat COVID-19 in Acutely Symptomatic Non-Hospitalized Participants
Verified date | March 2023 |
Source | Clene Nanomedicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multi-site, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of ZnAg liquid solution in symptomatic participants with acute COVID-19 that are not hospitalized at the time of enrollment.
Status | Completed |
Enrollment | 296 |
Est. completion date | October 20, 2022 |
Est. primary completion date | May 28, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 90 Years |
Eligibility | Inclusion Criteria: 1. Adults, aged 40 - 90 years (inclusive) 2. Acute onset (within 96 hours of the Baseline visit) of two or more COVID-19 symptoms self-rated as moderate-to-severe, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, sore throat, congestion, or runny nose, ageusia, anosmia, nausea, tingling or numbness in the extremities, or shortness of breath. 3. Laboratory-confirmed SARS-CoV-2 infection as determined by positive PCR in a sample collected = 96 hours prior to the Baseline visit. 4. PGI-Severity and CGI-Severity assessments of 'Mild', 'Moderate, or 'Severe' at the Screening visit (e.g., cannot be 'Normal'). 5. Participant (or legally authorized representatives) provides informed consent prior to the initiation of any study procedures. 6. Participant is willing and able to follow all study procedures and assessments according to the study protocol. 7. Participant is able to consume 60 ml of fluid orally twice daily. 8. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of study. Exclusion Criteria: 1. Unable or unwilling to take ZnAg liquid solution or matching placebo as directed. 2. Hospitalized prior to Baseline for COVID-19 management. 3. Need for hospitalization and/or ventilatory support at Baseline. 4. The emergence of any disease during study, other than COVID-19 that could better explain the participants' signs and symptoms. 5. Severe disease: respiratory distress, or requiring supplemental oxygen, or SpO2 = 93% on room air, or tachypnea (respiratory rate = 30 breaths/min) at Baseline. 6. History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (NYHA class 3 or 4). 7. Legal incapacity or limited legal capacity. 8. Women of childbearing potential who do not agree to use either abstinence or at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of the study. 9. Pregnant or breastfeeding. 10. Participation in another clinical study with an investigational product within the prior 12 months (per Resolution 251/1997). |
Country | Name | City | State |
---|---|---|---|
Brazil | Casa de Saúde | Campinas | Sau Paulo |
Brazil | Projeto Praca Onze | Centro | Rio De Janeiro |
Brazil | IBPClin | Gloria | Rio De Janeiro |
Brazil | PROCAPE | Santo Amaro | Recife |
Brazil | IPECC | Sao Paulo | State Of Sau Paulo |
Lead Sponsor | Collaborator |
---|---|
Clene Nanomedicine | Azidus Brazil, ICL Pharma |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of alive hospital free days at Day 28. | Days from baseline participant remains alive. | 28 days | |
Other | Mean change from Baseline to Day 8, Day 14, Day 21, and Day 28 in SARS-CoV-2 viral load. | Mean change from Baseline to Day 8, Day 14, Day 21, and Day 28 in SARS-CoV-2 viral load (Cycle Thresholds, Ct) , and time to non-detectable virus levels assessed by RT-qPCR. | Up to 28 days | |
Other | Change from Baseline to Day 8, Day 14, Day 21, and 28 in the slope of oxygen saturation levels (SpO2) assessed per protocol. | Oxygen saturation will be obtained after the participant has been resting for 5 minutes. | up to 28 days | |
Other | Clinical Global Impression (CGI) Severity and Change measures from Baseline to Day 8, Day 14, Day 21, and 28. | Measured by changes in participant rated Clinical Global Impression. | Up to 28 days | |
Other | Patient Global Impression (PGI) Severity and Change measures from Baseline to Day 8, Day 14, Day 21, and 28. | Measured by changes in participant rated Patient Global Impression. | Up to 28 days | |
Other | Change in the area under the curve for Net Symptom Burden from Baseline to Day 8, Day 14, Day 21, and 28. | Summary measure integrating semi-daily serial assessments of a subject's symptom count and severity over the duration of the study. | Up to 28 days | |
Other | Change in clinical status from Baseline to Day 8, Day 14, Day 21, and Day 28. | Assessed by the Clinical Status Ordinal Scale established in the remdesivir ACTT study. Scale is 1-8, with 1 being the least severe and 8 being the most severe (death). | Up to 28 days | |
Other | All-cause mortality rate at Day 28. | Rate of deceased participants at day 28. | 28 days | |
Other | Proportion of subjects who have not returned to "normal" at the day 21 and day 28 visits. | Proportion of subjects who do not have a PGI-Severity or CGI-Severity assessment of "normal" at the day 21 and day 28 visits. | 28 days | |
Primary | Time to substantial alleviation of COVID-19 symptoms. | Time to substantial alleviation of COVID-19 symptoms up to 28-days, over a continuous period = 48 hours (confirmed symptom resolution), defined as PGI-Severity of 'Normal' in Participants whose Baseline PGI-Severity value was 'Mild'; or, a PGI-Severity of 'Normal' or 'Mild' in participants whose Baseline PGI-Severity value was 'Moderate' or 'Severe'. | Up to 28 days. | |
Secondary | Time to complete alleviation of COVID-19 symptoms. | Time to complete alleviation of COVID-19 symptoms up to 28- days, over a continuous period = 48 hours (confirmed symptom resolution). | Up to 28 days. | |
Secondary | Proportion of participants who are hospitalized, requires hospitalization or are deceased. | Proportion of participants who are hospitalized, require hospitalization, or are deceased from Baseline to Day 28. Hospitalization will be determined by Investigator's clinical judgement. Where applicable, Investigators should follow local recommendations for hospitalization of patients with COVID-19 within their institution. | Up to 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |